Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells

Hideaki Iseki, Tien C. Ko, Xiang Ying Xue, Annie Seapan, Mark Hellmich, Courtney Townsend

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background. Olomoucine and roscovitine are novel compounds that are designed to inhibit cyclin-dependent kinases (e.g., Cdk2 and cdc2). Cdks regulate progression through key checkpoints of the cell cycle. The purpose of this study was to determine (1) whether olomoucine and roscovitine inhibit Cdk2 and cdc2 kinase activities of the human gastric cancer cell line SIIA and (2) whether olomoucine and roscovitine block cell proliferation and cell cycle progression. Methods. SIIA cells were treated with olomoucine or roscovitine and examined for Cdk2 and cdc2 activities by using histone Hi as the substrate. Cell numbers were counted with a Coulter counter. Cell cycle distribution wax analyzed by DNA flow cytometry. Results. Olomoucine and roscovitine completely blocked Cdk2 and cdc2 activities in SIIA cells. Both compounds were also able to inhibit proliferation of SIIA cells, as well as three other human gastric cancer cell lines (AGS, MKN45-630, and SNU-1). Cell cycle analysis showed that treatment with olomoucine or roscovitine for 24 hours led to a decrease in the S phase population and an increase in the G2/M population. Conclusions. We have shown that Cdk inhibitors, olomoucine and roscovitine, are a new class of anti neoplastic molecules with potential therapeutic benefits for gastric cancers.

Original languageEnglish (US)
Pages (from-to)187-195
Number of pages9
JournalSurgery
Volume122
Issue number2
DOIs
StatePublished - Aug 1997

Fingerprint

Cyclin-Dependent Kinases
Stomach Neoplasms
Cell Cycle
Cell Proliferation
Cell Line
Waxes
Cell Cycle Checkpoints
olomoucine
roscovitine
S Phase
Human Activities
Histones
Population
Flow Cytometry
Phosphotransferases
Cell Count
DNA

ASJC Scopus subject areas

  • Surgery

Cite this

Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. / Iseki, Hideaki; Ko, Tien C.; Xue, Xiang Ying; Seapan, Annie; Hellmich, Mark; Townsend, Courtney.

In: Surgery, Vol. 122, No. 2, 08.1997, p. 187-195.

Research output: Contribution to journalArticle

Iseki, Hideaki ; Ko, Tien C. ; Xue, Xiang Ying ; Seapan, Annie ; Hellmich, Mark ; Townsend, Courtney. / Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. In: Surgery. 1997 ; Vol. 122, No. 2. pp. 187-195.
@article{0d4e1487ac87444cbf07312cfd328066,
title = "Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells",
abstract = "Background. Olomoucine and roscovitine are novel compounds that are designed to inhibit cyclin-dependent kinases (e.g., Cdk2 and cdc2). Cdks regulate progression through key checkpoints of the cell cycle. The purpose of this study was to determine (1) whether olomoucine and roscovitine inhibit Cdk2 and cdc2 kinase activities of the human gastric cancer cell line SIIA and (2) whether olomoucine and roscovitine block cell proliferation and cell cycle progression. Methods. SIIA cells were treated with olomoucine or roscovitine and examined for Cdk2 and cdc2 activities by using histone Hi as the substrate. Cell numbers were counted with a Coulter counter. Cell cycle distribution wax analyzed by DNA flow cytometry. Results. Olomoucine and roscovitine completely blocked Cdk2 and cdc2 activities in SIIA cells. Both compounds were also able to inhibit proliferation of SIIA cells, as well as three other human gastric cancer cell lines (AGS, MKN45-630, and SNU-1). Cell cycle analysis showed that treatment with olomoucine or roscovitine for 24 hours led to a decrease in the S phase population and an increase in the G2/M population. Conclusions. We have shown that Cdk inhibitors, olomoucine and roscovitine, are a new class of anti neoplastic molecules with potential therapeutic benefits for gastric cancers.",
author = "Hideaki Iseki and Ko, {Tien C.} and Xue, {Xiang Ying} and Annie Seapan and Mark Hellmich and Courtney Townsend",
year = "1997",
month = "8",
doi = "10.1016/S0039-6060(97)90008-8",
language = "English (US)",
volume = "122",
pages = "187--195",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells

AU - Iseki, Hideaki

AU - Ko, Tien C.

AU - Xue, Xiang Ying

AU - Seapan, Annie

AU - Hellmich, Mark

AU - Townsend, Courtney

PY - 1997/8

Y1 - 1997/8

N2 - Background. Olomoucine and roscovitine are novel compounds that are designed to inhibit cyclin-dependent kinases (e.g., Cdk2 and cdc2). Cdks regulate progression through key checkpoints of the cell cycle. The purpose of this study was to determine (1) whether olomoucine and roscovitine inhibit Cdk2 and cdc2 kinase activities of the human gastric cancer cell line SIIA and (2) whether olomoucine and roscovitine block cell proliferation and cell cycle progression. Methods. SIIA cells were treated with olomoucine or roscovitine and examined for Cdk2 and cdc2 activities by using histone Hi as the substrate. Cell numbers were counted with a Coulter counter. Cell cycle distribution wax analyzed by DNA flow cytometry. Results. Olomoucine and roscovitine completely blocked Cdk2 and cdc2 activities in SIIA cells. Both compounds were also able to inhibit proliferation of SIIA cells, as well as three other human gastric cancer cell lines (AGS, MKN45-630, and SNU-1). Cell cycle analysis showed that treatment with olomoucine or roscovitine for 24 hours led to a decrease in the S phase population and an increase in the G2/M population. Conclusions. We have shown that Cdk inhibitors, olomoucine and roscovitine, are a new class of anti neoplastic molecules with potential therapeutic benefits for gastric cancers.

AB - Background. Olomoucine and roscovitine are novel compounds that are designed to inhibit cyclin-dependent kinases (e.g., Cdk2 and cdc2). Cdks regulate progression through key checkpoints of the cell cycle. The purpose of this study was to determine (1) whether olomoucine and roscovitine inhibit Cdk2 and cdc2 kinase activities of the human gastric cancer cell line SIIA and (2) whether olomoucine and roscovitine block cell proliferation and cell cycle progression. Methods. SIIA cells were treated with olomoucine or roscovitine and examined for Cdk2 and cdc2 activities by using histone Hi as the substrate. Cell numbers were counted with a Coulter counter. Cell cycle distribution wax analyzed by DNA flow cytometry. Results. Olomoucine and roscovitine completely blocked Cdk2 and cdc2 activities in SIIA cells. Both compounds were also able to inhibit proliferation of SIIA cells, as well as three other human gastric cancer cell lines (AGS, MKN45-630, and SNU-1). Cell cycle analysis showed that treatment with olomoucine or roscovitine for 24 hours led to a decrease in the S phase population and an increase in the G2/M population. Conclusions. We have shown that Cdk inhibitors, olomoucine and roscovitine, are a new class of anti neoplastic molecules with potential therapeutic benefits for gastric cancers.

UR - http://www.scopus.com/inward/record.url?scp=0030868409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030868409&partnerID=8YFLogxK

U2 - 10.1016/S0039-6060(97)90008-8

DO - 10.1016/S0039-6060(97)90008-8

M3 - Article

VL - 122

SP - 187

EP - 195

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -